Understanding loin pain in IgA nephropathy
Part of Immune system & allergy, Kidney & urinary, Pain, Women’s health & pregnancy clinical trials.
This study is looking at what causes loin pain (pain in your side or back) in people with IgA nephropathy. Researchers will use MRI scans to understand the pain better, which may help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have IgA nephropathy confirmed by a kidney biopsy.
- You have episodes of loin pain (pain in your side or back) at least once every 6 months.
- You are able to give informed consent to participate.
- You do not have any other kidney disease.
- You are not on dialysis and have not had a kidney transplant.
- You are not taking certain immune-suppressing medications like steroids or complement inhibitors.
- You do not have implants that prevent you from having an MRI (like a pacemaker or cochlear implant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes how people with IgA nephropathy respond to standard and newer treatments in everyday medical practice, to understand why some cases are resistant to therapy.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
This trial tests an investigational medication for two rare kidney conditions that cause inflammation and protein in the urine. It aims to see if the drug is safe and helps control the disease, potentially slowing kidney damage.
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.